Denosumab for low bone mass in hemodialysis patients: a noncontrolled trial

Am J Kidney Dis. 2015 Jul;66(1):175-7. doi: 10.1053/j.ajkd.2015.03.012. Epub 2015 May 13.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Biomarkers
  • Bone Density Conservation Agents / therapeutic use*
  • Bone Resorption / drug therapy*
  • Calcitriol / therapeutic use
  • Calcium / therapeutic use
  • Chronic Kidney Disease-Mineral and Bone Disorder / blood
  • Chronic Kidney Disease-Mineral and Bone Disorder / drug therapy*
  • Chronic Kidney Disease-Mineral and Bone Disorder / etiology
  • Cinacalcet
  • Contraindications
  • Denosumab
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hydroxycholecalciferols / therapeutic use
  • Hypocalcemia / chemically induced
  • Hypocalcemia / prevention & control
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / therapy
  • Male
  • Middle Aged
  • Naphthalenes / therapeutic use
  • Osteoclasts / drug effects
  • Prospective Studies
  • RANK Ligand / immunology
  • Renal Dialysis* / adverse effects

Substances

  • Antibodies, Monoclonal, Humanized
  • Biomarkers
  • Bone Density Conservation Agents
  • Hydroxycholecalciferols
  • Naphthalenes
  • RANK Ligand
  • TNFSF11 protein, human
  • Denosumab
  • Calcitriol
  • Calcium
  • Cinacalcet
  • alfacalcidol